Related Experiment Video

Updated: Jun 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

241

Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024)

Binbin Cheng1, Jinke Lv2, Yao Xiao3

  • 1Central Laboratory, Wenzhou Medical University Lishui Hospital, Lishui People's Hospital, Lishui, Zhejiang 323000, China; Hubei Polytechnic University, Huangshi, Hubei 435003, China.

European Journal of Medicinal Chemistry
|December 9, 2024
PubMed

Insights

Small molecule immuno-oncology agents offer advantages over antibodies for cancer immunotherapy, addressing limitations like tissue penetration and cost. These agents show promise for enhancing existing treatments and achieving synergistic effects.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody-based cancer immunotherapies demonstrate high targeting efficacy but face challenges including poor tissue penetration, limited oral bioavailability, short half-lives, high production costs, and immunogenicity.
  • Small molecule immuno-oncology agents present favorable pharmacokinetic profiles and improved safety, offering potential solutions to antibody limitations.

Purpose of the Study:

  • To review recent advancements (2020-2024) in small molecule inhibitors targeting key immune checkpoints in cancer.
  • To highlight the rational design, benefits, and limitations of these small molecule agents.
  • To outline the future prospects of small-molecule immunotherapy in oncology.

Main Methods:

  • Literature review of scientific publications from 2020-2024.
  • Focus on small molecule inhibitors targeting immune checkpoints such as PD-1/PD-L1, CTLA4, VISTA, TIM-3, and LAG3.
  • Analysis of rational drug design, therapeutic benefits, and potential drawbacks.

Main Results:

  • Small molecule inhibitors targeting PD-1/PD-L1, CTLA4, VISTA, TIM-3, and LAG3 have shown significant progress.
  • These agents offer improved pharmacokinetic properties and potentially reduced toxicity compared to antibodies.
  • Combination therapies involving small molecules and antibodies may yield synergistic anti-cancer effects.

Conclusions:

  • Small molecule immuno-oncology agents are poised to overcome limitations of antibody-based therapies.
  • They represent a promising strategy to augment current cancer treatments and explore novel therapeutic combinations.
  • Further research into small-molecule immunotherapy holds significant potential for advancing cancer treatment paradigms.
Keywords:
CTLA4Cancer immunotherapyLAG-3PD-1/PD-L1TIM-3VISTA

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338